The trading price of Merck & Co Inc (NYSE:MRK) closed lower on Firday, October 25, and closing at $103.98, -1.79% lower than its previous close.
Traders who pay close attention to intraday price movement should know that it fluctuated between $103.86 and $106.49. The company’s P/E ratio in the trailing 12-month period was 19.27, while its 5Y monthly beta was 0.399. In examining the 52-week price action we see that the stock hit a 52-week high of $134.63 and a 52-week low of $99.80. Over the past month, the stock has lost -8.06% in value.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Merck & Co Inc, whose market valuation is $263.57 billion at the time of this writing, is expected to release its quarterly earnings report in November. The dividend yield on the company stock is 2.96%, while its Forward Dividend ratio is 3.08. Investors’ optimism about the company’s current quarter earnings report is understandable. Analysts have predicted the quarterly earnings per share to grow by 1.51 per share this quarter, however they have predicted annual earnings per share of 7.74 for current year and 9.71 for next year.
Analysts have forecast the company to bring in revenue of 16.45B for the current quarter, with the likely lows of 15.8B and highs of 16.97B. From the analysts’ viewpoint, the consensus estimate for the company’s annual revenue is 64.1B.
On the technical side, indicators suggest MRK has a 100% Sell on average for the short term. According to the data of the stock’s medium term indicators, the stock is currently averaging as a 100% Sell, while an average of long term indicators suggests that the stock is currently 100% Sell.
Here is the average analyst rating on the stock as represented by 1.00 to 5.00, with the extremes of 1.00 and 5.00 suggesting the stock should be considered as either strong buy or strong sell respectively. The number of analysts that have assigned MRK a recommendation rating is 19. Out of them, 0 rate it a Hold, while 19 recommend Buy, whereas 0 assign an Overweight rating. 0 analyst(s) have tagged Merck & Co Inc (MRK) as Underweight, while 0 advise Sell. Analysts have rated the stock Buy, likely urging investors to take advantage of the opportunity to add to their holdings of the company’s shares.
If we dig deeper into the stock’s outlook, we see that the stock’s PEG is 0.79, which symbolizes a positive outlook. A quick review shows that MRK’s price is currently -4.87% off the SMA20 and -8.33% off the SMA50. The RSI metric on the 14-day chart is currently showing 26.02, and weekly volatility stands at 1.77%. When measured over the past 30 days, the indicator reaches 1.59%. Merck & Co Inc (NYSE:MRK)’s beta value is currently sitting at 0.40, while the Average True Range indicator is currently displaying 1.85. With analysts defining $80-$294 as the low and high price targets, we arrive at a consensus price target of $132 for the trailing 12-month period. The current price is about 23.06% off the estimated low and -182.75% off the forecast high, based on this estimate. Investors will be thrilled if MRK’s share price rises to $132, which is the median consensus price. At that level, MRK’s share price would be -26.95% below current price.
To see how Merck & Co Inc stock has been performing in comparison to its peers in the industry, here are the numbers: MRK stock’s performance was -1.79% in the latest trading, and 0.34% in the past year. Merck & Co Inc has a P/E ratio of 19.27.
An evaluation of the daily trading volume of Merck & Co Inc (NYSE:MRK) indicates that the 3-month average is 9.83 million. However, this figure has increased over the past 10 days to an average of 9.32.
Currently, records show that 2.53 billion of the company’s shares remain outstanding. The insiders hold 0.10% of outstanding shares, whereas institutions hold 78.87%. The stats also highlight that short interest as of 2024-10-15, stood at 26.04 million shares, resulting in a short ratio of 2.71 at that time. From this, we can conclude that short interest is 103.00 of the company’s total outstanding shares. It is noteworthy that short shares in October were up slightly from the previous month’s figure, which was 24.81 million. However, since the stock’s price has seen -4.62% year-to-date, investors’ interest is likely to be reignited due to its potential to move even lower.
